Matthew P Ward1, Anita Gupta2, John M Wo2, Bartek Rajwa3, John B Furness4, Terry L Powley5, Thomas V Nowak2. 1. Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA; Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: mpward@purdue.edu. 2. Indiana University School of Medicine, Indianapolis, IN, USA. 3. Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA. 4. Department of Anatomy and Neuroscience, University of Melbourne, Parkville, Australia; Florey Institute of Neuroscience and Mental Health, Parkville, Australia. 5. Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA; Dept. of Psychological Sciences, Purdue University, West Lafayette, IN, USA.
Abstract
BACKGROUND: Gastric electrical stimulation (GES) can be a life-changing, device-based treatment option for drug-resistant nausea and vomiting associated with diabetic or idiopathic gastroparesis (GP). Despite over two decades of clinical use, the mechanism of action remains unclear. We hypothesize a vagal mechanism. NEW METHOD: Here, we describe a noninvasive method to investigate vagal nerve involvement in GES therapy in 66 human subjects through the compound nerve action potential (CNAP). RESULTS: Of the 66 subjects, 28 had diabetic GP, 35 had idiopathic GP, and 3 had postsurgical GP. Stimulus charge per pulse did not predict treatment efficacy, but did predict a significant increase in total symptom score in type 1 diabetics as GES stimulus charge per pulse increased (p < 0.01), representing a notable side effect and providing a method to identify it. In contrast, the number of significant left and right vagal fiber responses that were recorded directly related to patient symptom improvement. Increased vagal responses correlated with significant decreases in total symptom score (p < 0.05). COMPARISON WITH EXISTING METHOD(S): We have developed transcutaneous recording of cervical vagal activity that is synchronized with GES in conscious human subjects, along with methods of discriminating the activity of different nerve fiber groups with respect to conduction speed and treatment response. CONCLUSIONS: Cutaneous vagal CNAP analysis is a useful technique to unmask relationships among GES parameters, vagal recruitment, efficacy and side-effect management. Our results suggest that CNAP-guided GES optimization will provide the most benefit to patients with idiopathic and type 1 diabetic gastroparesis.
BACKGROUND: Gastric electrical stimulation (GES) can be a life-changing, device-based treatment option for drug-resistant nausea and vomiting associated with diabetic or idiopathic gastroparesis (GP). Despite over two decades of clinical use, the mechanism of action remains unclear. We hypothesize a vagal mechanism. NEW METHOD: Here, we describe a noninvasive method to investigate vagal nerve involvement in GES therapy in 66 human subjects through the compound nerve action potential (CNAP). RESULTS: Of the 66 subjects, 28 had diabeticGP, 35 had idiopathic GP, and 3 had postsurgical GP. Stimulus charge per pulse did not predict treatment efficacy, but did predict a significant increase in total symptom score in type 1 diabetics as GES stimulus charge per pulse increased (p < 0.01), representing a notable side effect and providing a method to identify it. In contrast, the number of significant left and right vagal fiber responses that were recorded directly related to patient symptom improvement. Increased vagal responses correlated with significant decreases in total symptom score (p < 0.05). COMPARISON WITH EXISTING METHOD(S): We have developed transcutaneous recording of cervical vagal activity that is synchronized with GES in conscious human subjects, along with methods of discriminating the activity of different nerve fiber groups with respect to conduction speed and treatment response. CONCLUSIONS: Cutaneous vagal CNAP analysis is a useful technique to unmask relationships among GES parameters, vagal recruitment, efficacy and side-effect management. Our results suggest that CNAP-guided GES optimization will provide the most benefit to patients with idiopathic and type 1 diabetic gastroparesis.
Authors: Jinhong Xing; Frederick Brody; Michael Rosen; J D Z Chen; Edy Soffer Journal: Am J Physiol Gastrointest Liver Physiol Date: 2003-02-12 Impact factor: 4.052
Authors: Thomas L Abell; Eric Van Cutsem; Hasse Abrahamsson; Jan D Huizinga; J W Konturek; Jean Paul Galmiche; Guy VoelIer; Ludo Filez; Bernt Everts; William E Waterfall; W Domschke; Stanislas Bruley des Varannes; Babajide O Familoni; Ivan M Bourgeois; Jozef Janssens; Gervais Tougas Journal: Digestion Date: 2002 Impact factor: 3.216
Authors: Charles C Horn; Kelly Meyers; Audrey Lim; Matthew Dye; Diana Pak; Linda Rinaman; Bill J Yates Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-01-15 Impact factor: 3.619
Authors: Calvin D Eiber; Sophie C Payne; Natalia P Biscola; Leif A Havton; Janet R Keast; Peregrine B Osborne; James B Fallon Journal: J Neural Eng Date: 2021-11-25 Impact factor: 5.379
Authors: Leo K Cheng; Nipuni D Nagahawatte; Recep Avci; Peng Du; Zhongming Liu; Niranchan Paskaranandavadivel Journal: Front Neurosci Date: 2021-04-22 Impact factor: 5.152